Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5273334 | 0.90 | MGLL (0.42) | MGLLKDM1APTGS2PTGS1EPHX2 | |
| SCHEMBL14529221 | 0.89 | MGLL (0.44) | MGLLKDM1APTGS2PTGS1EPHX2 | |
| SCHEMBL5272729 | 0.85 | MGLL (0.47) | MGLLKDM1APTGS2PTGS1EPHX2 | |
| SCHEMBL4924326 | 0.83 | MGLL (0.41) | MGLLPTGS2PTGS1EPHX2NTRK1 | |
| SCHEMBL5271865 | 0.83 | MGLL (0.44) | MGLLKDM1APTGS2PTGS1EPHX2 | |
| SCHEMBL5266809 | 0.80 | MGLL (0.45) | MGLLPTGS2PTGS1EPHX2NTRK1 | |
| SCHEMBL5269913 | 0.80 | MGLL (0.41) | MGLLPTGS2PTGS1EPHX2MALT1 | |
| SCHEMBL4927600 | 0.80 | CCKAR (0.42) | MGLLKDM1APTGS2PTGS1EPHX2 | |
| SCHEMBL14529769 | 0.80 | NTRK1 (0.48) | KDM1ANTRK1 | |
| SCHEMBL5269984 | 0.79 | RPA1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | MGLL 4176/4885KDM1A 1118/4885PTGS2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.